8/4/2020  4:50:18 PM Chg. -2.00 Volume Bid4:51:23 PM Ask4:51:44 PM Market Capitalization Dividend Y. P/E Ratio
261.00CHF -0.76% 61,637
Turnover: 10.67 mill.
260.00Bid Size: 351 261.00Ask Size: 513 831.76 mill.CHF 0.00% -

Business description

Operating under the "Zur Rose" and "DocMorris" brands, the Swiss-based Zur Rose Group is one of Europe's leading online pharmacy and one of Switzerland's foremost wholesale suppliers to medical practitioners. With its business model, it offers high-quality, safe and cost-effective pharmaceutical care and thus contributes to reducing healthcare costs. It is also characterized by the continuous further development of digital services in the field of drug management in order to increase therapy safety. The creation of added value and a pronounced patient orientation make the Group an important strategic partner for service providers, cost units and industry. The Zur Rose Group serves the Swiss market from Frauenfeld, Switzerland. In Germany and Austria, the Group operates through subsidiaries in Heerlen (Netherlands) and Halle an der Saale (Germany). Furthermore, it holds a majority interest in BlueCare in Winterthur, one of the leading providers of networking systems in the Swiss healthcare market.
 

Management board & Supervisory board

CEO
Walter Oberhänsli
Management board
Marcel Ziwica, Bernd Gschaider, Betül Susamis Unaran, David Masó, Olaf Heinrich, Walter Hess
Supervisory board
Dr. Christian Mielsch, Dr. Thomas Schneider, Florian Seubert, Prof. Dr. Volker Amelung, Prof. Stefan Feuerstein, Tobias Hartmann, Walter Oberhänsli
 

Company data

Name: Zur Rose Group AG
Address: Seestrasse 119,CH-8266 Steckborn
Phone: +41-52-7240020
Fax: +41-52-7240015
E-mail: info@zurrose.com
Internet: www.zurrosegroup.com
Industry: Consumer Goods
Sector: Retailers
Sub sector: -
End of financial year: 12/31
Free Float: 64.48%
IPO date: 7/6/2017

Investor relations

Name: Marcel Ziwica
IR phone: +41-52-7240064
IR Fax: -
IR e-mail: marcel.ziwica@zurrose.com

Company calendar

CW 34 | 8/19/2020 Interim Report 2nd Quarter/6 Months
CW 43 | 10/21/2020 Interim Report 3rd Quarter/9 Months
 

Main Shareholders

Freefloat
 
64.48%
Vanessa Frey; Beat Frey; Brigitte Frey; Alexandra Frey
 
10.30%
T. Rowe Price Associates, Inc.
 
5.69%
Al Faisaliah Group Holding Company
 
4.57%
Christiane Maria Bülow-Bichler; Ulrich Johannes Spindler; Tobias Bodo Kindlieb; Frank Müller
 
4.25%
Mitglieder des Verwaltungsrats und der Gruppenleitung
 
4.00%
Portsea Asset Management LLP
 
3.52%
Patrick Schmitz-Morkamer; Patrick Bierbaum
 
3.19%